Accuracy of TomoTherapy treatments for superficial target volumes

Helical tomotherapy is a technique for delivering intensity modulated radiation therapy treatments using a continuously rotating linac. In this approach, fan beams exiting the linac are dynamically modulated in synchrony with the motion of the gantry and couch. Helical IMRT deliveries have been applied to treating surface lesions, and the purpose of this study was to evaluate the accuracy of dose calculated by the TomoTherapy Hi·Art treatment planning system for superficial planning target volumes (PTVs). TomoTherapy treatment plans were developed for three superficial PTVs (2-, 4-, and 6-cm deep radially by 90°azimuthally by 4-cm longitudinally) contoured on a 27-cm diameter cylindrical white opaque, high-impact polystyrene phantom. The phantom included removable transverse and sagittal film cassettes that contained bare Kodak EDR2 films cut such that their edges matched the phantom surface (±0.05 cm). The phantom was aligned to the machine's isocenter (±0.05 cm) and was irradiated according to the treatment plans. Films were scanned with a Vidar film digitizer, and optical densities were converted to dose using a calibration determined from a 6 MV perpendicular film exposure. This perpendicular calibration required that axial film doses (parallel irradiation) be scaled by 1.02 so that mid-arc depth doses matched those measured in the sagittal plane (perpendicular irradiation). All film readings were scaled by 0.935 to correct for over-response due to phantom Cerenkov light. Measured dose distributions were registered to calculated ones and compared. Calculated doses overpredicted measured doses by as much as 9.5% of the prescribed dose at depths less than 1 cm. At depths greater than 1 cm, calculated dose distributions showed agreement to measurement within 5% in the high-dose region and within 0.2 cm distance-to-agreement in the dose falloff regions. In the low-dose region posterior to the PTVs (<10% of the prescribed dose), the dose algorithm underpredicted the dose by 1%-2% of the prescribed dose. Clinically, it is recommended that 1 cm of bolus be used on the surface to ensure that cancerous tissues less than 1 cm depth are not underdosed.